 |
|
|
| |
Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Co-infected with Hepatitis C Virus and Human Immunodeficiency Virus-1: The EXPEDITION-2 Study
|
| |
| |
Reported by Jules Levin
IAS ⋅ Paris, France⋅ 24 July 2017
Jurgen K Rockstroh1, Karine Lacombe2, Rolando M. Viani3, Chloe Orkin4, David Wyles5, Anne F Luetkemeyer6, Ruth Soto-Malave7, Robert Flisiak8, Sanjay Bhagani9, Kenneth E. Sherman10, Tatiana Shimonova11, Peter Ruane12, Joseph Sasadeusz13, Jihad Slim14, Zhenzhen Zhang3, Teresa I. Ng3, Abhishek Gulati3, Roger Trinh3, Mark Sulkowski15
1Universitatsklinikum Bonn, Bonn, Germany; 2. Inserm UMR‐S1136, Universite Pierre et Marie Curie, Hopital Saint‐Antoine, APHP, Paris; 3. AbbVie Inc., North Chicago, Illinois, USA; 4. The Royal London Hospital, London, UK; 5. Denver Health Medical Center, Denver, Colorado, United States; 6. Zuckerberg San Francisco General, San Francisco, CA, USA; 7. Innovative Care P.S.C., Bayamon, Puerto Rico; 8. Klinika Chorob Zakaznych i Hepatologii UM w Biaymstoku, Biaystok, Poland; 9. Royal Free London Foundation Trust, London, UK; 10. University of Cincinnati, Cincinnati, OH 11 . State budgetary Healthcare Institution Infectious Clinical Hospital #2 of Moscow City Healthcare Department, Moscow, Russia; 12. Ruane Medical & Liver Health Institute, Los Angeles, California, United States; 13. Royal Melbourne Hospital, Parkville,Victoria, Australia; 14. St. Michael's Medical Center, Newark, NJ, United States; 15. Johns Hopkins University School of Medicine,Baltimore, Maryland, USA
CROI: GLECAPREVIR AND PIBRENTASVIR INTERACTIONS WITH COMBINATION ANTIRETROVIRAL REGIMENS - (02/20/17)
|
| |
|
|
|
|
|
